Taro Pharma Acquires Alchemee from Galderma

Taro Pharmaceutical Industries Ltd., a US based subsidiary of India’s largest drugmaker Sun Pharma has announced its acquisition of Alchemee, formerly The Proactiv Company (TPC), from Galderma. The acquisition includes Alchemee’s business and assets worldwide, including the Proactiv® brand.

Taro markets a broad range of prescription and over-the-counter products and has a growing line of solid dosage form products used mainly in cardiology and neurology, is also a leading manufacturer and supplier of topical dermatological products in the United States. Alchemee’s acquisition will help Taro to boost its dermatology portfolio in the US market.

“This acquisition demonstrates Taro’s commitment to strengthening our position in the over-the-counter dermatology space,” said Uday Baldota, Taro’s CEO. “In addition to adding Proactiv® to our product portfolio, we are also gaining the omni-channel marketing capabilities and expertise of the Alchemee team. We look forward to working with them to continue Proactiv®’s legacy as an iconic brand synonymous with acne care.”

Proactiv, an Acne Medication

Proactiv®, Alchemee’s flagship brand, is an acne medication used by millions around the world for more than 25 years. Originally set up as a subscription-based business, Proactiv® quickly became a leading U.S. consumer acne brand. Proactiv’s dermatologist-tested approach to skincare also known as “Combination Therapy ® ” comprises three unique acne treatment systems each with three synergistic steps. With Combination Therapy, Proactiv® claims to have the right system to help the customer achieve and maintain clear, healthy-looking skin. 

“We are excited for Alchemee and its marquee brand, Proactiv®, to join the expansive Taro portfolio of prescription and over-the-counter dermatology products,” said Shannon Pappas, Global Head of Alchemee. “This strategic move further positions Alchemee for continued growth in the skincare space.”

Author

Arvind C. Shekhar